Psychiatry Medical News about methamphetamine clinical pharmacology

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A review of the clinical pharmacology of methamphetamine
Addiction, 06/29/09

Cruickshank CC et al. - Repeated use may induce neurotoxicity, associated with prolonged psychiatric symptoms, cognitive impairment and an increased risk of developing Parkinson's disease. Abrupt cessation of repeated methamphetamine use leads to a withdrawal syndrome consisting of depressed mood, anxiety and sleep disturbance.

Methods

Relevant literature was identified through a PubMed search.
Additional literature was obtained from relevant books and monographs.

Results

The mean elimination half-life for methamphetamine is approximately 10 hours, with considerable inter-individual variability in pharmacokinetics.
Direct effects at low-to-moderate methamphetamine doses (5-30 mg) include arousal, positive mood, cardiac stimulation and acute improvement in cognitive domains such as attention and psychomotor coordination.
At higher doses used typically by illicit users (≥50 mg), methamphetamine can produce psychosis.
Its hypertensive effect can produce a number of acute and chronic cardiovascular complications.
Acute withdrawal lasts typically for 7-10 days, and residual symptoms associated with neurotoxicity may persist for several months.

<< Previous
Occurrence of depression in families with frontotemporal...

Next >>
Age at onset and clinical features of late life compulsive...

Methamphetamine Body Stuffers: An Observational Case Series
Annals of Emergency Medicine, 10/13/09 Relevance Score: 78%

Clinical pharmacology of analgesics in old age and frailty
Reviews in Clinical Gerontology, 11/10/09 Relevance Score: 68%

Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of COPD
American Journal of Respiratory and Critical Care Medicine, 10/30/09 Relevance Score: 67%

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Journal of Clinical Oncology, 10/20/09 Relevance Score: 67%

Prospective clinical trial: enteral nutrition during maintenance infliximab in Crohns disease
Journal of Gastroenterology, 10/06/09 Relevance Score: 67%